A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Colorectal Cancer
Cholangiocarcinoma
Bladder Cancer
Ovarian Cancer
Gastric Cancer
Palpable Subcutaneous Malignant Lesions
Renal Cell Carcinoma
Melanoma
Epithelial Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions

BIOLOGICAL: TRK-950
BIOLOGICAL: TRK-950
BIOLOGICAL: TRK-950
DRUG: Irinotecan
DRUG: Leucovorin
DRUG: 5-FU
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Ramucirumab
DRUG: Paclitaxel
DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Imiquimod Cream
DRUG: Bevacizumab
DRUG: PLD

Sponsor

Toray Industries, Inc